DiaSorin

DiaSorin
Società per azioni
Traded as BIT: DIA
Industry Biotechnology
Founded 2000 (2000)
Headquarters Saluggia, Italy
Key people
 Gustavo Denegri (Chairman)
Carlo Rosa (CEO)
Products In vitro diagnostics instruments and services
Revenue Increase€443.8 million[1] (2014)
Number of employees
 1,620 (2014)[1]
Website www.diasorin.com

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics.[2] The group was founded in 2000 and is headquartered in Saluggia, Italy.

The production platform of the Group is now divided into several plants located in Europe, the United States and Africa: Saluggia, Dietzenbach (Germany), Stillwater, Minnesota (US), Dublin (Ireland), Dartford (UK) and Kyalami (South Africa).[1]

The company is a constituent of the FTSE Italia Mid Cap index.

In March 2016, the company announced it would acquire Quest Diagnostics’ Focus Diagnostics immunodiagnostic and molecular diagnostic division for $300 million.[3]

Activities

DiaSorin is focusing its efforts to 8 fields of immunodiagnostics: Infectious diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Gastro-Intestinal infections, Autoimmunity and Brain and Cardiac markers.

The company is also active in molecular diagnostics for infectious diseases and for the detection of some forms of Leukemia.[1]

Shareholder base

Shareholder (2015[4]) Share %
Finde SS 43.957%
Rosa Carlo 8.540%
Oppenheimerfunds Inc, 4.800%
Even Chen Menachem 4.466%
Threadneedle Asset Management Holdings Ltd 3.690%
Market 34.547%

Financial data

DiaSorin is listed since 2007 in the Italian Stock Exchange and today in the FTSE Italy Mid Cap Index.

(in thousand Euros)[1] 2007 2008 2009 2010 2011 2012 2013 2014
Sales and service revenues 206,367 244,612 304,129 404,547 440,003 433,763 434,849 443,770
Cost of sales (73,827) (84,010) (90,484) (119,812) (126,145) (136,420) (135,187) (145,032)
Gross profit 132,540 160,602 213,645 284,735 313,858 297,343 299,662 298,738
EBIT 47,576 70,790 106,438 145,517 163,307 140,259 134,693 129,891
Profit before taxes 44,135 59,887 103,733 144,932 158,256 137,406 129,339 128,124
Net result 26,367 37,459 70,047 90,418 99,607 87,684 83,111 84,074
EBITDA 61,519 85,618 123,636 167,112 190,020 169,558 163,098 160,290

Notes

  1. 1 2 3 4 5 "Annual Financial Report at December 31, 2014". Retrieved 3 July 2015.
  2. ↑ "About us". Retrieved 24 November 2013.
  3. ↑ "DiaSorin to Acquire Quest's Focus Diagnostics for $300M". GEN.
  4. ↑ "Diasorin official website, At a glance". Retrieved 8 July 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.